Literature DB >> 18455697

Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels.

Philip S Y Tsang1, Huy Trinh, Ruel T Garcia, Jeanine T Phan, Nghiem B Ha, Huy Nguyen, Khanh Nguyen, Emmet B Keeffe, Mindie H Nguyen.   

Abstract

BACKGROUND & AIMS: Serum ALT remains the most accessible test available to clinicians for monitoring chronic hepatitis B virus infection, but appropriate action when ALT levels are only mildly elevated is ambiguous in standard guidelines.
METHODS: A retrospective study was conducted to investigate the prevalence of significant histology in a patient population with mildly elevated serum ALT levels. A total of 193 consecutive patients were selected and divided into 2 groups according to HBeAg status. Patients were further divided into cohorts on the basis of their highest ALT elevation during follow-up and whether it was 1-1.5 times the upper limit of normal (ULN), 1.5-2 times the ULN, or greater than twice the ULN. The ULN that was used is 30 U/L for men and 19 U/L for women.
RESULTS: In all cohorts there was a substantial fraction of patients with histologic disease as evaluated by liver biopsy. HBeAg-negative patients were older, had lower viral load, and had a higher prevalence of disease. After adjustments for age, HBeAg status and HBV DNA viral load were not predictors of significant histology. Age >35 years, male gender, and increasing ALT levels were predictors for significant histology on multivariate analysis.
CONCLUSIONS: A substantial proportion of patients with mildly elevated ALT levels have significant histologic disease. The prevalence increased with the higher ALT levels and age.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455697     DOI: 10.1016/j.cgh.2008.02.037

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  20 in total

1.  Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans.

Authors:  Yu-Nan Hsu; Calvin Q Pan; Ali Abbasi; Victor Xia; Raghav Bansal; Ke-Qin Hu
Journal:  Dig Dis Sci       Date:  2014-02-12       Impact factor: 3.199

Review 2.  Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.

Authors:  Ahmad Najib Azmi; Soek-Siam Tan; Rosmawati Mohamed
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

3.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

4.  Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study.

Authors:  Sue Zhang; Jessica T Ristau; Huy N Trinh; Ruel T Garcia; Huy A Nguyen; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2012-03-31       Impact factor: 3.199

5.  Development and validation of a model to predict advanced fibrosis in chronic hepatitis B virus-infected patients with high viral load and normal or minimally raised ALT.

Authors:  Seung Ha Park; Chang Hoon Kim; Dong Joon Kim; Jae Youn Cheong; Sung Won Cho; Seong Gyu Hwang; Youn Jae Lee; Mong Cho; Jin Mo Yang; Young Bae Kim
Journal:  Dig Dis Sci       Date:  2010-11-18       Impact factor: 3.199

6.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

7.  Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.

Authors:  L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-01       Impact factor: 8.171

8.  Monitoring during and after antiviral therapy for hepatitis B.

Authors:  Karin L Andersson; Raymond T Chung
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 9.  DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.

Authors:  Rafael Bárcena Marugán; Silvia García Garzón
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

10.  Histological changes in chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal.

Authors:  En-Qiang Chen; Fei-Jun Huang; Ling-Li He; Lang Bai; Li-Chun Wang; Tao-You Zhou; Xue-Zhong Lei; Cong Liu; Hong Tang
Journal:  Dig Dis Sci       Date:  2009-02-25       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.